BioAge Labs experienced a dramatic selloff in morning trading, with shares sliding about 59.6% after Novo Nordisk disclosed that its Phase 3 ZEUS trial of ziltivekimab failed to demonstrate a reduction in major adverse cardiovascular events compared with placebo. The study enrolled more than 6,300 patients who had atherosclerotic cardiovascular disease, chronic kidney disease, and elevated inflammation, and reported a hazard ratio of 0.99.
The ZEUS result delivered a direct and immediate read-through to BioAge because the company has placed substantial strategic emphasis on its cardiovascular inflammation program. BioAge’s lead clinical candidate, BGE-102, is an oral NLRP3 inhibitor currently being evaluated in the QUELL-CV Phase 2 study in patients with obesity and elevated systemic inflammation. Management had highlighted BGE-102’s potential value to investors, and the program had recently advanced with the dosing of the first participant in QUELL-CV.
Investors’ concern intensified because BioAge had previously reported Phase 1 data for BGE-102 showing significant reductions in high-sensitivity C-reactive protein (hsCRP), the same inflammatory biomarker that ziltivekimab successfully suppressed in ZEUS. Despite the biomarker response in ZEUS, the Phase 3 trial did not translate biomarker reductions into a statistically significant clinical benefit for major cardiovascular outcomes. That disconnect raised questions about whether lowering inflammatory markers in this patient population will reliably reduce heart attacks and strokes, irrespective of the specific therapeutic mechanism used.
Market conditions provided little support on the session. Broad U.S. indexes were weaker, with the S&P 500 slipping 0.4%, the Dow Jones Industrial Average down 0.3%, and the Nasdaq easing 0.4%. Other companies exposed to cardiovascular inflammation also sold off; Monte Rosa Therapeutics was among the names that recorded sharp declines on the same news, illustrating how the ZEUS failure reverberated across the sector.
The trading pushed BioAge well under its 52-week high of $25.96, though the stock remained above its 52-week low of $4.11. The combination of an unexpected Phase 3 failure from a well-resourced peer, the direct scientific overlap with BioAge’s own clinical program, and a risk-off tone in the broader biotech sector combined to produce one of the steepest single-session declines in BioAge’s history. Investors moved to reassess the probability of success for programs targeting cardiovascular inflammation across the board.
For companies with exposure to the cardiovascular inflammation hypothesis, the ZEUS outcome represents a material reevaluation point. The trial’s definitive outcome from a high-profile sponsor undercut the assumption that biomarker suppression necessarily leads to improved clinical outcomes in this patient population.